NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 21 of 24
Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
NCT02302274
Building Skill in Heart Failure Self-care: A Community Based Intervention
NCT01894750
RAD001 Plus Carboplatin in Breast Cancer Patients
NCT01127763
Living With Aphasia: An International Study
NCT01234090
Improving Communication of Medication Instructions to Parents
NCT01834924
The Research Registry for Neonatal Lupus
NCT00074373
Community-based Approaches to Treating Hypertension and Colon Cancer Prevention
NCT01092078
Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
NCT01180647
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
NCT01105702
Study of Botulinum Toxin and Recovery of Hand Function After Stroke
NCT01422161
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
NCT01091259
Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)
NCT01070394
Practice-based Trial of Blood Pressure Control in African Americans
NCT01070056
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
NCT01198509
Comparison of CTI Ablation Prior to or After LA Ablation for AF
NCT02325778
DECIFER: Depression and Citalopram In First Episode Recovery
NCT01041274
Study to Assess Platelet Dysfunction With Verify Now Assay
NCT01167218
The Safety and Tolerability of Kinetin, in Patients With Familial Dysautonomia
NCT02274051
Study of Prone Accelerated Breast And Nodal IMRT
NCT02308488
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NCT00973739
Promoting Adherence to Sleep Apnea Treatment Among Blacks With Metabolic Syndrome
NCT01946659
Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol
NCT01377636
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NCT01003938
Image Guided Therapy in the Treatment of Gliomas
NCT01263821
DREAM Project Community Health Worker Intervention
NCT02041598
Band Holiday Study
NCT00967122
Periprocedural Glycemic Control in Patients Undergoing Coronary Angiography
NCT01419652
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
NCT00933608
Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV
NCT00952133
Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors
NCT00935545
A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT00952081
A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol
NCT03274817
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
NCT00878436
Serial Phlebotomy in Voluntary Blood Donors
NCT02762422
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
NCT00899574
Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests
NCT00907855
Enoxaparin and/or Minocycline in Acute Stroke
NCT00836355
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
NCT01289353
Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
NCT01114815
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
NCT01000662
Psilocybin Cancer Anxiety Study
NCT00957359
Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV
NCT00826345
Asthma Education Using Child Life Services and an Asthma-based Computer Game
NCT01072123
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
NCT00814255
Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids
NCT00850928
Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
NCT00958581
Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
NCT00835159
Comparison of Antibiotic Protocols in Spine Patients With Postoperative Drains
NCT01608854
High Water Intake to Slow Progression of Polycystic Kidney Disease
NCT00784030
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
NCT00843310
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.